4
Changes in Ownership
CORCEPT THERAPEUTICS INC Filed Acc 0001193125-25-196319
Chief Development Officer sold 20,000 shares at an average $70.49 ($1,409,848)
- Chief Development Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Guyer William Chief Development Officer | 2025-09-02 | Option exercise 10b5-1 | +20,000 | $21.65 | $433,000 | 25,487 | D: show line 1 in the form |
| Guyer William Chief Development Officer | 2025-09-02 | Sale 10b5-1 | −15,594 | $70.39 | $1,097,693 | 9,893 | D: show line 2 in the form |
| Guyer William Chief Development Officer | 2025-09-02 | Sale 10b5-1 | −4,406 | $70.85 | $312,155 | 5,487 | D: show line 3 in the form |
| Open-market sales · 20,000 sh · avg $70.49 · $1,409,848 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Guyer William Chief Development Officer | 2025-09-02 | Option exercise · Stock option (right to buy) 10b5-1 | −20,000 | 330,000 | D: show line 4 in the form |
Loading xslF345X05/ownership.xml…